Welcome to our dedicated page for Biote SEC filings (Ticker: BTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biote Corp. filings document the public-company disclosures of a Nasdaq-listed hormone optimization and healthy aging business. Recent Form 8-K reports furnish quarterly and annual operating results, including procedure revenue, dietary supplement revenue, margins, adjusted EBITDA measures and commercial-priorities commentary for the Biote-certified provider network.
The company’s SEC record also includes Regulation FD investor presentation filings, definitive proxy materials for annual meeting matters, and securities information for its Class A common stock. Other material-event filings address operational and financial effects of a voluntary recall involving specific hormone pellet lots shipped by Asteria Health, Biote’s wholly owned 503B manufacturer of compounded bioidentical hormones.
biote Corp. amended and restated the employment agreement for Robert Peterson in connection with his role as Interim Chief Executive Officer. Under the new terms, he will receive an annual base salary of $658,800 plus eligibility for an annual incentive of up to 72.5% of base salary.
Peterson will be granted stock options to purchase a number of shares equal to 0.56% of biote’s outstanding common stock as of June 8, 2026, with an additional option grant for the same percentage if he becomes non-interim CEO. The agreement provides 12 months of salary and health insurance benefits if he is terminated without cause or resigns for specified good reasons, with enhanced payments (salary plus target bonus and accelerated vesting of certain equity awards) if such a termination occurs around a change in control.
biote Corp. interim CEO Robert Charles Peterson received a grant of stock options as part of his compensation. The award covers 206,746 options to purchase Class A common stock at an exercise price of $2.46 per share and expires on June 11, 2036. According to the vesting terms, 25% of the options will vest on June 12, 2027, with the remaining options vesting in 36 substantially equal monthly installments, subject to his continued service. Following this grant, Peterson holds 206,746 stock options directly, and the filing does not report any open-market share purchases or sales.
biote Corp. director Bret Christensen received a grant of stock options, giving him the right to buy 130,000 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.
All 130,000 option shares will vest on the earlier of June 8, 2027 or the day before biote Corp.'s 2027 Annual Meeting of Stockholders, as long as Christensen remains in continuous service through that vesting date.
biote Corp. Executive Chairman Marc D. Beer received a grant of employee stock options covering 114,157 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.
According to the vesting schedule, 25% of the options vest on June 8, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 114,157 derivative securities related to these options.
Biote Corp. announced a leadership transition while keeping its 2026 outlook intact. Bret Christensen will step down as Chief Executive Officer of BioTE effective June 8, 2026, but will remain on the Board as a Class III director and receive a new stock option for 130,000 shares as part of a separation agreement. Robert Peterson, currently Chief Financial Officer and Chief Business Officer, will become Interim Chief Executive Officer and join the Board as a Class I director, continuing to serve as principal financial officer. The Board also appointed Marc Beer as Executive Chairman, with annual base compensation of $521,200, an annual bonus opportunity of up to 85% of base pay, and an option to purchase 114,157 shares.
Under Mr. Beer’s services agreement, if his role ends without cause or he resigns for specified good reason around a change in control, he is entitled to 18 months of salary and target bonus continuation, COBRA premium payments for up to 18 months, and full vesting of certain equity awards. In its accompanying press release, Biote reaffirmed full-year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of 2026, signaling that management expects to pursue existing growth and profitability plans despite the CEO transition.
biote Corp. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class I directors, Andrew R. Heyer and Dana Jacoby, to serve until the 2029 annual meeting and until their successors are elected and qualified or earlier departure.
Heyer received 22,759,692 votes for and 3,960,800 withheld, while Jacoby received 23,020,635 votes for and 3,699,857 withheld. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 29,507,419 votes for, 67,387 against, and 7,390 abstentions.
biote Corp. director Andrew R. Heyer reported equity-based compensation awards. He received a stock option covering 130,000 shares of Class A Common Stock at an exercise price of $2.2000 per share, expiring on May 11, 2036. All shares under this option vest on the earlier of May 12, 2027 or the day before the company’s 2027 annual stockholder meeting, subject to his continuous service. He also received 35,259 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested at grant but will settle only when he separates from service, and his Deferred Settlement RSU balance increased to 81,382 units after this award.
biote Corp. director Debra L. Morris reported compensation-related equity activity. She exercised derivative rights tied to Deferred Settlement RSUs into 21,407 shares of Class A Common Stock and now directly holds 71,562 common shares. She also received awards of 130,000 stock options with a $2.20 exercise price, expiring in 2036, and 39,036 Deferred Settlement RSUs that are fully vested but settle at future dates as described in the award terms.
biote Corp. director Stephen Mark Cone received new equity awards in the form of options and deferred settlement RSUs. He was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, vesting in full on the earlier of May 12, 2027 or the day prior to the 2027 annual meeting, subject to continued service.
He also received 31,481 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, but settlement is deferred until his separation from service. Following these awards, he holds 130,000 options and 69,822 Deferred Settlement RSUs directly.
biote Corp. director Dana Lynn Jacoby received new equity awards. She was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, expiring on May 11, 2036. These options vest on the earlier of May 12, 2027 or the day prior to the company’s 2027 annual stockholders meeting, subject to continued service.
She also received 37,777 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, with settlement deferred until calendar year 2027 or her separation from service, whichever occurs first. Following these awards, she holds 130,000 options and 59,364 Deferred Settlement RSUs directly.